Cannabidiol and Marihuana Research Expansion Act

H.R. 3797, Medical Marijuana Research Act, S. 2032, Cannabidiol and Marijuana Research Expansion Act, to lower the barriers of researching marijuana.

Client expense: $10,000 · Firm income: Not reported

Government targets: Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Small Business Administration (SBA), White House Office

H.R. 3797, Medical Marijuana Research Act, S. 2032, Cannabidiol and Marijuana Research Expansion Act, to lower the barriers of researching marijuana.

Client expense: $10,000 · Firm income: Not reported

Government targets: Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Small Business Administration (SBA), White House Office

Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, cancer survivorship, federal health care programs, genetic information, cancer, nutrition, tanning beds, clinical trials, skin cancer, cannabis research, and wellness, including: HR 6514, Worker Health Coverage Protection Act HR 1425, Patient Protection and Affordable Care Enhancement Act Issues related to regulations for implementing section 1557 of the Affordable Care Act on anti-discrimination HR 6800, Health and Economic Recovery Omnibus Emergency Solutions Act or The HEROES Act Issues related to the Senate HELP Committee initiative on preparing for future pandemics. Regulatory issues related to telehealth Issues related to surprise medical billing, including HR 3630, the No Surprises Act; S 1895, the Lower Health Care Costs Act; S 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019; Issues relating to curbing health care costs; H.R.647 & S. 2080, the Palliative Care and Hospice Education and Training Act; Anti-cancer medication cost-sharing parity respecting H.R. 1409; A national family caregiving strategy respecting S. 1719 and H.R. 1028; Access to medicines respecting FDA implementation of right to try law; Introduction of the S. 3404 & H.R. 6102, Verifying Accurate Leading-edge IVCT Development Act of 2020 or the VALID Act of 2020; H. Res. 282, supporting initiatives to encourage parents and guardians to take measures to prevent sunburns in minors they care for; H.R. 1966 & S 946, the Henrietta Lacks Enhancing Cancer Research Act of 2019, regarding decreasing disparities in access to cancer clinical trials; Additional issues related to reducing health disparities in cancer clinical trials; Issues related to capturing racial and ethnic data demographic data for communities disproportionately affected by coronavirus; H.R. 2222 and S. 1107, the Women and Lung Cancer Research and Preventative Services Act; H.Res. 14 & S.Res. 223, Expressing support for the designation of DIPG Awareness Day H.R. 1730 and S. 741, the Cancer Drug Parity Act; Cannabis research issues, including S. 2032 Cannabidiol and Marihuana Research Expansion Act and S. 2400Expanding Cannabis Research and Information Act ; H.R. 4078 & S. 2424 EARLY Act Reauthorization of 2019 S. 2497, the Dependent Income Exclusion Act; Issues related to HHS regulation of prescription drug prices and costs; H.R. 4439, Creating Hope Reauthorization Act; H.R. 1730 and S. 741, the Cancer Drug Parity Act; H.R. 6556, the Gabriella Miller Kids First Research Act 2.0; H.R. 4439 & S. 4010, the Creating Hope Reauthorization Act; H.R.6666 & S. 4315, the COVID-19 Testing, Reaching, And Contacting Everyone (TRACE) Act, bill related to support needed data collection efforts to begin to contain coronavirus; Issues related to cancer survivorship and transitions of care from oncology treatment back to primary care; Issues related to improving data collection during the COVID-19 pandemic; and H.Res 1125, which expresses support for prioritizing racial and ethnic diversity in clinical trials for therapies, diagnostics in clinical trials for therapies, diagnostics, and vaccines for COVID -19. S 4557, COVID Enrollment Response Act (Sen. Baldwin)

Client expense: $490,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Energy, Dept of, Environmental Protection Agency (EPA), Federal Reserve System, Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), Veterans Affairs, Dept of (VA), White House Office

Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, cancer survivorship, federal health care programs, genetic information, cancer, nutrition, tanning beds, clinical trials, skin cancer, cannabis research, and wellness, including: HR 6514, Worker Health Coverage Protection Act HR 1425, Patient Protection and Affordable Care Enhancement Act Issues related to regulations for implementing section 1557 of the Affordable Care Act on anti-discrimination HR 6800, Health and Economic Recovery Omnibus Emergency Solutions Act or The HEROES Act Issues related to the Senate HELP Committee initiative on preparing for future pandemics. Regulatory issues related to telehealth Issues related to surprise medical billing, including HR 3630, the No Surprises Act; S 1895, the Lower Health Care Costs Act; S 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019; Issues relating to curbing health care costs; H.R.647 & S. 2080, the Palliative Care and Hospice Education and Training Act; Anti-cancer medication cost-sharing parity respecting H.R. 1409; A national family caregiving strategy respecting S. 1719 and H.R. 1028; Access to medicines respecting FDA implementation of right to try law; Introduction of the S. 3404 & H.R. 6102, Verifying Accurate Leading-edge IVCT Development Act of 2020 or the VALID Act of 2020; H. Res. 282, supporting initiatives to encourage parents and guardians to take measures to prevent sunburns in minors they care for; H.R. 1966 & S 946, the Henrietta Lacks Enhancing Cancer Research Act of 2019, regarding decreasing disparities in access to cancer clinical trials; Additional issues related to reducing health disparities in cancer clinical trials; Issues related to capturing racial and ethnic data demographic data for communities disproportionately affected by coronavirus; H.R. 2222 and S. 1107, the Women and Lung Cancer Research and Preventative Services Act; H.Res. 14 & S.Res. 223, Expressing support for the designation of DIPG Awareness Day H.R. 1730 and S. 741, the Cancer Drug Parity Act; Cannabis research issues, including S. 2032 Cannabidiol and Marihuana Research Expansion Act and S. 2400Expanding Cannabis Research and Information Act ; H.R. 4078 & S. 2424 EARLY Act Reauthorization of 2019 S. 2497, the Dependent Income Exclusion Act; Issues related to HHS regulation of prescription drug prices and costs; H.R. 4439, Creating Hope Reauthorization Act; H.R. 1730 and S. 741, the Cancer Drug Parity Act; H.R. 6556, the Gabriella Miller Kids First Research Act 2.0; H.R. 4439 & S. 4010, the Creating Hope Reauthorization Act; H.R.6666 & S. 4315, the COVID-19 Testing, Reaching, And Contacting Everyone (TRACE) Act, bill related to support needed data collection efforts to begin to contain coronavirus; Issues related to cancer survivorship and transitions of care from oncology treatment back to primary care; Issues related to improving data collection during the COVID-19 pandemic; and H.Res 1125, which expresses support for prioritizing racial and ethnic diversity in clinical trials for therapies, diagnostics in clinical trials for therapies, diagnostics, and vaccines for COVID -19. S 4557, COVID Enrollment Response Act (Sen. Baldwin)

Client expense: $490,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Energy, Dept of, Environmental Protection Agency (EPA), Federal Reserve System, Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), Veterans Affairs, Dept of (VA), White House Office

H.R. 3502, Protecting People from Surprise Medical Bills Act, all provisions H.R. 5826, Consumer Protections Against Surprise Medical Bills Act of 2020, all provisions H.R. 3630, No Surprises Act, all provisions S. 1895, Lower Health Care Costs Act, provisions relating to surprise billing S. 1531, Stopping The Outrageous Practice of (STOP) Surprise Medical Bills Act of 2019, all provisions S. 4421, Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act, all provisions H.R. 6644, To require group health plans and health insurance issuers offering group or individual health insurance coverage to provide coverage for services furnished via telehealth if such services would be covered if furnished in-person during the COVID-19 emergency, all provisions S. 3741, Health Care at Home Act of 2020, all provisions S. 4666, National Coronavirus Commission Act of 2020, all provisions S. 4507, Getting Early Treatment and Comprehensive Assessments Reduces Emergencies (GET CARE) Act of 2020, all provisions H.R. 8441, Frontline Heroes Act, all provisions S. 4317, SAFE TO WORK Act, all provisions H.R. 925, The Heroes Act, all provisions S. 3749, Public Health Emergency Privacy Act, all provisions S. 3861, Exposure Notification Privacy Act, all provisions H.R. 6585, Equitable Data Collection and Disclosure on COVID-19 Act, all provisions H.R. 7510, Assimilating Health and Equity Assessments into Decision-making (AHEAD Act) of 2020, all provisions S. 4919, Assimilating Health and Equity Assessments into Decision-making (AHEAD Act) of 2020, all provisions H.R. 6808, Health Force and Resilience Force Act of 2020, all provisions S. 3606, Health Force and Resilience Force Act of 2020, all provisions H.R. 7255, Coronavirus Health Care Worker Wellness Act of 2020, all provisions H.R. 8094, Dr. Lorna Breen Health Care Provider Protection Act, all provisions S. 4349, Dr. Lorna Breen Health Care Provider Protection Act, all provisions H.R. 3884, Marijuana Opportunity Reinvestment and Expungement (MORE) Act of 2020, all provisions S. 2032, Cannabidiol and Marihuana Research Expansion Act, all provisions H.R. 1503, Orange Book Transparency Act of 2019, provisions related to PBM and prescription drug price transparency H.R. 1520, Purple Book Continuity Act of 2019, provisions related to PBM and prescription drug price transparency H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act, provisions related to PBM and prescription drug price transparency H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act, provisions related to PBM and prescription drug price transparency H.R. 4995, Maternal Health Quality Improvement Act of 2020, all provisions H.R. 7120, George Floyd Justice in Policing Act of 2020, provisions relating to police reform Affordable Care Act stabilization Expansion of Paycheck Protection Program for 501(c)6s Public Health and Social Services Emergency Fund Marginalized and minoritized communities/COVID-19 disproportionate impact COVID-19 long haulers COVID-19 testing/vaccines/health care prior authorization COVID-19/treatment and prescribing flexibilities COVID-19/Expanded PPE/clearinghouses E/M services Surprise medical billing executive orders Surprise Medical Billing, generally Clinical and administrative data intersection State Medical Boards/Interstate Medical Licensure Compact Pharmacists and COVID-19 testing Mental health parity Digital therapeutics Physician practice financial impact 21st Century Cures Act/health data and privacy 42 CFR Part 2, HIPAA Patent reform CPT - digital Most favored nation drug pricing Drug pricing Health Information Technology/information blocking Dietary guidelines/alcohol consumption Data privacy Cyber security best practices Race and sex stereotyping executive order

Client expense: $3,870,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Bureau of Citizenship & Immigration Services (BCIS), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, Veterans Affairs, Dept of (VA), White House Office

HR 8179 Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2020; provisions related to the federal regulation of CBD S 2032 Cannabidiol and Marihuana Research Expansion Act FDA Cannabidiol Enforcement Policy: Draft Guidance for Industry

Client expense: $40,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Monitored regulations on hemp/CBD issues. Discussions relating to regulation of the CBD industry. Monitored discussions regarding H.R. 3797 Medical Marijuana Research Act. Monitored discussions regarding H.R. 3884 MORE Act of 2020. Monitored discussions regarding S. 2032 Cannabidiol and Marihuana Research Expansion Act.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES

H.R. 3502, Protecting People from Surprise Medical Bills Act, all provisions H.R. 5826, Consumer Protections Against Surprise Medical Bills Act of 2020, all provisions H.R. 3630, No Surprises Act, all provisions S. 1895, Lower Health Care Costs Act, provisions relating to surprise billing S. 1531, Stopping The Outrageous Practice of (STOP) Surprise Medical Bills Act of 2019, all provisions S. 4421, Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act, all provisions H.R. 6644, To require group health plans and health insurance issuers offering group or individual health insurance coverage to provide coverage for services furnished via telehealth if such services would be covered if furnished in-person during the COVID-19 emergency, all provisions S. 3741, Health Care at Home Act of 2020, all provisions S. 4666, National Coronavirus Commission Act of 2020, all provisions S. 4507, Getting Early Treatment and Comprehensive Assessments Reduces Emergencies (GET CARE) Act of 2020, all provisions H.R. 8441, Frontline Heroes Act, all provisions S. 4317, SAFE TO WORK Act, all provisions H.R. 925, The Heroes Act, all provisions S. 3749, Public Health Emergency Privacy Act, all provisions S. 3861, Exposure Notification Privacy Act, all provisions H.R. 6585, Equitable Data Collection and Disclosure on COVID-19 Act, all provisions H.R. 7510, Assimilating Health and Equity Assessments into Decision-making (AHEAD Act) of 2020, all provisions S. 4919, Assimilating Health and Equity Assessments into Decision-making (AHEAD Act) of 2020, all provisions H.R. 6808, Health Force and Resilience Force Act of 2020, all provisions S. 3606, Health Force and Resilience Force Act of 2020, all provisions H.R. 7255, Coronavirus Health Care Worker Wellness Act of 2020, all provisions H.R. 8094, Dr. Lorna Breen Health Care Provider Protection Act, all provisions S. 4349, Dr. Lorna Breen Health Care Provider Protection Act, all provisions H.R. 3884, Marijuana Opportunity Reinvestment and Expungement (MORE) Act of 2020, all provisions S. 2032, Cannabidiol and Marihuana Research Expansion Act, all provisions H.R. 1503, Orange Book Transparency Act of 2019, provisions related to PBM and prescription drug price transparency H.R. 1520, Purple Book Continuity Act of 2019, provisions related to PBM and prescription drug price transparency H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act, provisions related to PBM and prescription drug price transparency H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act, provisions related to PBM and prescription drug price transparency H.R. 4995, Maternal Health Quality Improvement Act of 2020, all provisions H.R. 7120, George Floyd Justice in Policing Act of 2020, provisions relating to police reform Affordable Care Act stabilization Expansion of Paycheck Protection Program for 501(c)6s Public Health and Social Services Emergency Fund Marginalized and minoritized communities/COVID-19 disproportionate impact COVID-19 long haulers COVID-19 testing/vaccines/health care prior authorization COVID-19/treatment and prescribing flexibilities COVID-19/Expanded PPE/clearinghouses E/M services Surprise medical billing executive orders Surprise Medical Billing, generally Clinical and administrative data intersection State Medical Boards/Interstate Medical Licensure Compact Pharmacists and COVID-19 testing Mental health parity Digital therapeutics Physician practice financial impact 21st Century Cures Act/health data and privacy 42 CFR Part 2, HIPAA Patent reform CPT - digital Most favored nation drug pricing Drug pricing Health Information Technology/information blocking Dietary guidelines/alcohol consumption Data privacy Cyber security best practices Race and sex stereotyping executive order

Client expense: $4,170,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Bureau of Citizenship & Immigration Services (BCIS), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, Veterans Affairs, Dept of (VA), White House Office

Extension of threshold for medical expense deduction H.R.3797- Medical Marijuana Research Act S.2032- Cannabidiol and Marihuana Research Expansion Act H.R. 7663- Protecting Access to Post-COVID-19 Telehealth Act of 2020 H.R.7078, the Evaluating Disparities and Outcomes of Telehealth During the COVID-19 Emergency Act of 2020 Expand eligibility for paid family and medical leave for high-risk individuals during the pandemic Telehealth guidelines for making the flexibilities permanent Medicaid non-emergency medical transportation (NEMT) Improving Seniors Timely Access to Care Act (H.R. 3107) S. 1384, the Prescription Drug Rebate Reform Act of 2019 S.475 - RxCAP Act of 2019 H.R. 945/S. 286, the Mental Health Access Improvement Act of 2019 H.R. 601 - Medical Cannabis Research Act of 2019 Support of an out-of-pocket spending cap for Medicare Part D Support for Value Based Arrangements in Medicare and Medicaid Coronavirus Aid, Relief, and Economic Security Act General information about Parkinson's disease, the need for research funding, and protecting access to care

Client expense: $18,500 · Firm income: Not reported

Government targets: Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

Issues related to the Food and Drug Administration. Issues related to the COVID-19 pandemic. Issues related to the cannabis research: S.2032: Cannabidiol and Marihuana Research Expansion Act. H.R.3797: Medical Marijuana Research Act. H.R.7614: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021. H.R.3884: MORE Act of 2020. H.R.133 [116TH]: Consolidated Appropriations Act, 2021.

Client expense: Not reported · Firm income: $60,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, cancer survivorship, federal health care programs, genetic information, cancer, nutrition, tanning beds, clinical trials, skin cancer, cannabis research, and wellness, including: HR 6514, Worker Health Coverage Protection Act HR 1425, Patient Protection and Affordable Care Enhancement Act Issues related to regulations for implementing section 1557 of the Affordable Care Act on anti-discrimination HR 6800, Health and Economic Recovery Omnibus Emergency Solutions Act or The HEROES Act Issues related to the Senate HELP Committee initiative on preparing for future pandemics. Regulatory issues related to telehealth Issues related to surprise medical billing, including HR 3630, the No Surprises Act; S 1895, the Lower Health Care Costs Act; S 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019; Issues relating to curbing health care costs; H.R.647 & S. 2080, the Palliative Care and Hospice Education and Training Act; Anti-cancer medication cost-sharing parity respecting H.R. 1409; A national family caregiving strategy respecting S. 1719 and H.R. 1028; Access to medicines respecting FDA implementation of right to try law; Introduction of the S. 3404 & H.R. 6102, Verifying Accurate Leading-edge IVCT Development Act of 2020 or the VALID Act of 2020; H. Res. 282, supporting initiatives to encourage parents and guardians to take measures to prevent sunburns in minors they care for; H.R. 1966 & S 946, the Henrietta Lacks Enhancing Cancer Research Act of 2019, regarding decreasing disparities in access to cancer clinical trials; Additional issues related to reducing health disparities in cancer clinical trials; Issues related to capturing racial and ethnic data demographic data for communities disproportionately affected by coronavirus; H.R. 2222 and S. 1107, the Women and Lung Cancer Research and Preventative Services Act; H.Res. 14 & S.Res. 223, Expressing support for the designation of DIPG Awareness Day H.R. 1730 and S. 741, the Cancer Drug Parity Act; Cannabis research issues, including S. 2032 Cannabidiol and Marihuana Research Expansion Act and S. 2400Expanding Cannabis Research and Information Act ; H.R. 4078 & S. 2424 EARLY Act Reauthorization of 2019 S. 2497, the Dependent Income Exclusion Act; Issues related to HHS regulation of prescription drug prices and costs; H.R. 4439, Creating Hope Reauthorization Act; H.R. 1730 and S. 741, the Cancer Drug Parity Act; H.R. 6556, the Gabriella Miller Kids First Research Act 2.0; H.R. 4439 & S. 4010, the Creating Hope Reauthorization Act; H.R.6666 & S. 4315, the COVID-19 Testing, Reaching, And Contacting Everyone (TRACE) Act, bill related to support needed data collection efforts to begin to contain coronavirus; Issues related to cancer survivorship and transitions of care from oncology treatment back to primary care; Issues related to improving data collection during the COVID-19 pandemic; and H.Res 1125, which expresses support for prioritizing racial and ethnic diversity in clinical trials for therapies, diagnostics in clinical trials for therapies, diagnostics, and vaccines for COVID -19. S 4557, COVID Enrollment Response Act (Sen. Baldwin)

Client expense: $490,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Energy, Dept of, Environmental Protection Agency (EPA), Federal Reserve System, Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), Veterans Affairs, Dept of (VA), White House Office

Food and Drug Administration (FDA) draft "Guidance for Industry: New Dietary Ingredient Notifications and Related Issues." Supports efforts to encourage FDA to develop a legal path for CBD as a new dietary ingredient. (no bill number) H.R.3055 - Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020 S.1215 - National Defense Authorization Act for Fiscal Year 2020 S.2032 - A bill to expand research on the cannabidiol and marihuana. S.1717/H.R. 3142 - SNAP Vitamin and Mineral Improvement Act of 2019 H.R.1887 - National Institute of Nutrition Act H.R.1595 - Secure And Fair Enforcement Banking Act of 2019 S.2895 - SARMs Control Act of 2019 S.1790 - National Defense Authorization Act for Fiscal Year 2020 H.R.1865 - Further Consolidated Appropriations Act, 2020 H.R.5587 - To amend the Federal Food, Drug, and Cosmetic Act with respect to the regulation of hemp-derived cannabidiol and hemp-derived cannabidiol containing substances.

Client expense: $146,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, Treasury, Dept of, Vice President of the U.S.

H.R. 2466: State Opioid Response Grant Authorization Act H.R. 2922: Respond Now Act H.R. 3496, S. 1983: Create Opportunities Act H.R. 2569, S. 1365: Comprehensive Addiction Resources Emergency Act H.R. 3797, Medical Marijuana Research Act S.2032, Cannabidiol and Marihuana Research Expansion Act Re-Authorize Residential Substance Abuse Treatment Act of 2020(Discussion draft, no bill number) S. 5000: CARA 2.0

Client expense: $216,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), Education, Dept of, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Natl Science Foundation (NSF), SENATE

H.R. 133 - United States-Mexico Economic Partnership Act [Consolidated Appropriations Act, 2021] S 2032 - Cannabidiol and Marijuana Research Expansion Act

Client expense: $10,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

H.R.7614, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2021, Provisions relating to NIH, substance use research Public Law 116-260, Consolidated Appropriations Act, 2021, Division H, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021, Provisions relating to NIH, substance use research Barriers to research resulting from DEA scheduling, Drug research related issues S. 2032, Cannabidiol & Marijuana Research Expansion Act, Drug abuse research related issues H.R.3797, Medical Marijuana Research Act of 2019, Drug abuse research related issues Monitor Drug abuse research related issues, as follows: Stop the Importation and Trafficking of Synthetic Analogues (SITSA) S.3148, Stopping Overdoses of Fentanyl Analogues Act H.R.2935/S.1622, Stopping Overdoses of Fentanyl Analogues Act Non Human Primates and Biomedical research

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

Issues related to controlled substances legislation and policy, including DOJ appropriations, IRS regulations, and taxation, and banking policies S.1028 - STATES Act H.R. 2093 - STATES Act H.R.5952 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2019 (section 542) H.R. 3884 - MORE Act of 2019 S.2032 - Cannabidiol and Marijuana Research Act FDA regulatory agenda

Client expense: Not reported · Firm income: $50,000

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE

H.R. 3797, Medical Marijuana Research Act, S. 2032, Cannabidiol and Marihuana Research Expansion Act, to lower the barriers of researching marijuana

Client expense: $20,000 · Firm income: Not reported

Government targets: Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Small Business Administration (SBA), White House Office

S. 4421, Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act, all provisions H.R. 5172, Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act, all provisions S. 3067, Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act\, all provisions H.R. 1503, Orange Book Transparency Act of 2019, all provisions H.R. 1520, Purple Book Continuity Act of 2019, all provisions H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act, all provisions H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act, all provisions H.R. 3502, Protecting People From Surprise Medical Bills Act, all provisions S. 1895, Lower Health Care Costs Act, provisions related to surprise billing H.R. 5826, Consumer Protections Against Surprise Medical Bills Act of 2020, all provisions H.R. 3630, No Surprises Act, all provisions S. 1531, Stopping The Outrageous Practice of (STOP) Surprise Medical Bills Act of 2019, all provisions S. 4666, A bill to establish the Commission on the Coronavirus Pandemic in the United States, all provisions S. 44507, Getting Early Treatment and Comprehensive Assessments Reduces Emergencies (GET CARE) Act of 2020, all provisions H.R. 8441, To establish certain protections and benefits for front line workers, and for other purposes, all provisions H.R. 925, The Heroes Act, provisions related to COVID-19 H.R. 6644, Health Care at Home Act of 2020, all provisions S. 3741, Health Care at Home Act of 2020, all provisions S. 3749, Public Health Emergency Privacy Act, all provisions S. 3861, Exposure Notification Privacy Act, all provisions H.R. 6585, Equitable Data Collection and Disclosure on COVID-19 Act, all provisions H.R. 7510, Assimilating Health and Equity Assessments into Decision-making (AHEAD) Act of 2020, all provisions H.R. 7255, Coronavirus Health Care Worker Wellness Act of 2020, all provisions H.R. 8094, Dr. Lorna Breen Health Care Provider Protection Act, all provisions S. 4349, Dr. Lorna Breen Health Care Provider Protection Act, all provisions H.R. 4995, Maternal Health Quality Improvement Act of 2020, all provisions H.R. 7120, George Floyd Justice in Policing Act of 2020, all provisions H.R. 2279, Safe Step Act, all provisions S. 4055, Strengthening America's Health Care Readiness Act, all provisions S. 2032, Cannabidiol and Marihuana Research Expansion Act, all provisions Essential Workforce Parity Act Affordable Care Act (ACA) stabilization Georgia's ACA Section 1332 waiver Public Health Emergency Fund/physician financial assistance/healthcare workforce support 21st Century Cures Act/health data and privacy Surprise medical billing Expanded Personal Protective Equipment (PPE)/clearinghouses Health equity Maternal mortality Marginalized and minoritized communities/COVID-19 disproportionate impact COVID-19/serology testing supply chain COVID-19/response strategy COVID-19/social distancing COVID-19/data collection COVID-19/ PPE/federal funding COVID-19/Vaccines COVID-19/pediatric vaccines/pharmacists and pharmacy interns COVID-19/Coding Pharmacists and COVID-19 testing Mental health parity 42 CFR Part 2, HIPAA Funding for pandemic planning and preparedness Physician burnout/suicide Telehealth waivers Augmented Intelligence (AI) Drug pricing/Executive Orders Health Quality Roadmap Datablocking Health breach notification rule Electronic health record (EHR) certification

Client expense: $4,260,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Education, Dept of, Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), President of the U.S., SENATE, State, Dept of (DOS), U.S. Immigration & Customs Enforcement (ICE), Veterans Affairs, Dept of (VA), White House Office

Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, cancer survivorship, federal health care programs, genetic information, cancer, nutrition, tanning beds, clinical trials, skin cancer, cannabis research, and wellness, including: HR 6514, Worker Health Coverage Protection Act HR 1425, Patient Protection and Affordable Care Enhancement Act Issues related to regulations for implementing section 1557 of the Affordable Care Act on anti-discrimination HR 6800, Health and Economic Recovery Omnibus Emergency Solutions Act or The HEROES Act Issues related to the Senate HELP Committee initiative on preparing for future pandemics. Regulatory issues related to telehealth Issues related to surprise medical billing, including HR 3630, the No Surprises Act; S 1895, the Lower Health Care Costs Act; S 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019; Issues relating to curbing health care costs; H.R.647 & S. 2080, the Palliative Care and Hospice Education and Training Act; Anti-cancer medication cost-sharing parity respecting H.R. 1409; A national family caregiving strategy respecting S. 1719 and H.R. 1028; Access to medicines respecting FDA implementation of right to try law; Introduction of the S. 3404 & H.R. 6102, Verifying Accurate Leading-edge IVCT Development Act of 2020 or the VALID Act of 2020; H.R. 4897 & S. 2358 Women and Lung Cancer Research and Preventive Services Act of 2018; H. Res. 282, supporting initiatives to encourage parents and guardians to take measures to prevent sunburns in minors they care for; H.R. 1966 & S 946, the Henrietta Lacks Enhancing Cancer Research Act of 2019, regarding decreasing disparities in access to cancer clinical trials; Additional issues related to reducing health disparities in cancer clinical trials; Issues related to capturing racial and ethnic data demographic data for communities disproportionately affected by coronavirus; H.R. 2222 and S. 1107, the Women and Lung Cancer Research and Preventative Services Act; H.Res. 14 & S.Res. 223, Expressing support for the designation of DIPG Awareness Day H.R. 1730 and S. 741, the Cancer Drug Parity Act; Cannabis research issues, including S. 2032 Cannabidiol and Marihuana Research Expansion Act and S. 2400Expanding Cannabis Research and Information Act ; H.R. 2689 & S. 1438 the Breast Cancer Research Stamp Reauthorization Act H.R. 4078 & S. 2424 EARLY Act Reauthorization of 2019 S. 2497, the Dependent Income Exclusion Act; Issues related to HHS regulation of prescription drug prices and costs; H.R. 4439, Creating Hope Reauthorization Act; H.R. 1730 and S. 741, the Cancer Drug Parity Act; H.R. 6556, the Gabriella Miller Kids First Research Act 2.0; H.R. 4439 & S. 4010, the Creating Hope Reauthorization Act; H.R.6666 & S. 4315, the COVID-19 Testing, Reaching, And Contacting Everyone (TRACE) Act, bill related to support needed data collection efforts to begin to contain coronavirus; Issues related to cancer survivorship and transitions of care from oncology treatment back to primary care; Issues related to improving data collection during the COVID-19 pandemic; and H.Res 1125, which expresses support for prioritizing racial and ethnic diversity in clinical trials for therapies, diagnostics in clinical trials for therapies, diagnostics, and vaccines for COVID -19. S 4557, COVID Enrollment Response Act (Sen. Baldwin)

Client expense: $815,440 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Energy, Dept of, Environmental Protection Agency (EPA), Federal Reserve System, Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), Veterans Affairs, Dept of (VA), White House Office

Issues related to the Food and Drug Administration. Issues related to the COVID-19 pandemic. Issues related to the cannabis research. S.2032: Cannabidiol and Marihuana Research Expansion Act. H.R.7614: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021.

Client expense: Not reported · Firm income: $60,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

H.R.7614, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2021, Provisions relating to NIH, substance use research Barriers to research resulting from DEA scheduling, Drug research related issues S. 2032, Cannabidiol & Marijuana Research Expansion Act, Drug abuse research related issues H.R.3797, Medical Marijuana Research Act of 2019, Drug abuse research related issues Monitor Drug abuse research related issues, as follows: Stop the Importation and Trafficking of Synthetic Analogues (SITSA) S.3148, Stopping Overdoses of Fentanyl Analogues Act H.R.2935/S.1622, Stopping Overdoses of Fentanyl Analogues Act S.2701, Federal Initiative to Guarantee Health by Targeting Fentanyl Act H.R.5421, Stopping Illicit Trafficking Act of 2019 Public Law 116-114, Temporary Reauthorization and Study of the Emergency Scheduling of Fentanyl Analogues Act Public Law 115-334, Agriculture Improvement Act of 2018, Hemp related provision Non Human Primates and Biomedical research H.R.601, Medical Cannabis Research Act Coronavirus, Healthcare research related issues

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

Issues related to controlled substances legislation and policy, including DOJ appropriations, IRS regulations, and taxation, and banking policies S.1028 - STATES Act H.R. 2093 - STATES Act H.R.5952 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2019 (section 542) H.R. 3884 - MORE Act of 2019 S.2032 - Cannabidiol and Marijuana Research Act FDA regulatory agenda

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office

Food and Drug Administration (FDA) draft "Guidance for Industry: New Dietary Ingredient Notifications and Related Issues." Supports efforts to encourage FDA to develop a legal path for CBD as a new dietary ingredient. (no bill number) H.R.3055 - Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020 S.1215 - National Defense Authorization Act for Fiscal Year 2020 S.2032 - A bill to expand research on the cannabidiol and marihuana. S.1717/H.R. 3142 - SNAP Vitamin and Mineral Improvement Act of 2019 H.R.1887 - National Institute of Nutrition Act H.R.1595 - Secure And Fair Enforcement Banking Act of 2019 S.2895 - SARMs Control Act of 2019 S.1790 - National Defense Authorization Act for Fiscal Year 2020 H.R.1865 - Further Consolidated Appropriations Act, 2020 H.R.5587 - To amend the Federal Food, Drug, and Cosmetic Act with respect to the regulation of hemp-derived cannabidiol and hemp-derived cannabidiol containing substances.

Client expense: $140,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, Treasury, Dept of, Vice President of the U.S.

H.R. 3797, Medical Marijuana Research Act, S. 2032, Cannabidiol and Marihuana Research Expansion Act, to lower the barriers of researching marijuana

Client expense: $20,000 · Firm income: Not reported

Government targets: Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Small Business Administration (SBA), White House Office

Issues related to the Food and Drug Administration. Issues related to the COVID-19 pandemic. Issues related to the cannabis research. S.2032: Cannabidiol and Marihuana Research Expansion Act. S.4049: National Defense Authorization Act for Fiscal Year 2021.

Client expense: Not reported · Firm income: $60,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

Issues related to controlled substances legislation and policy, including DOJ appropriations, IRS regulations, and taxation, and banking policies S.1028 - STATES Act H.R. 2093 - STATES Act H.R.5952 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2019 (section 542) H.R. 3884 - MORE Act of 2019 S.2032 - Cannabidiol and Marijuana Research Act FDA regulatory agenda

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office

Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2021, Provisions relating to NIH, substance use research Drug abuse research related issues, as follows: Stop the Importation and Trafficking of Synthetic Analogues (SITSA) Barriers to research resulting from DEA scheduling S.3148, Stopping Overdoses of Fentanyl Analogues Act H.R.2935/S.1622, Stopping Overdoses of Fentanyl Analogues Act S.2701, Federal Initiative to Guarantee Health by Targeting Fentanyl Act H.R.5421, Stopping Illicit Trafficking Act of 2019 Public Law 116-114, Temporary Reauthorization and Study of the Emergency Scheduling of Fentanyl Analogues Act Monitor Drug abuse research related issues, as follows: S. 2032, Cannabidiol & Marijuana Research Expansion Act H.R.3797, Medical Marijuana Research Act of 2019 Public Law 115-334, Agriculture Improvement Act of 2018, Hemp related provision Non Human Primates and Biomedical research H.R.601, Medical Cannabis Research Act Coronavirus, Healthcare research related issues

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

H.R. 3797, Medical Marijuana Research Act, S. 2032, Cannabidiol and Marihuana Research Expansion Act, to lower the barriers of researching marijuana

Client expense: $30,000 · Firm income: Not reported

Government targets: Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Small Business Administration (SBA), White House Office

Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, cancer survivorship, federal health care programs, genetic information, cancer, nutrition, tanning beds, clinical trials, skin cancer, cannabis research, and wellness, including: HR 6514, Worker Health Coverage Protection Act HR 1425, Patient Protection and Affordable Care Enhancement Act Issues related to regulations for implementing section 1557 of the Affordable Care Act on anti-discrimination HR 6800, Health and Economic Recovery Omnibus Emergency Solutions Act or The HEROES Act Issues related to the Senate HELP Committee initiative on preparing for future pandemics. Regulatory issues related to telehealth Issues related to surprise medical billing, including HR 3630, the No Surprises Act; S 1895, the Lower Health Care Costs Act; S 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019; Issues relating to curbing health care costs; H.R.647 & S. 2080, the Palliative Care and Hospice Education and Training Act; Anti-cancer medication cost-sharing parity respecting H.R. 1409; A national family caregiving strategy respecting S. 1719 and H.R. 1028; Access to medicines respecting FDA implementation of right to try law; Introduction of the S. 3404 & H.R. 6102, Verifying Accurate Leading-edge IVCT Development Act of 2020 or the VALID Act of 2020; H.R. 4897 & S. 2358 Women and Lung Cancer Research and Preventive Services Act of 2018; H. Res. 282, supporting initiatives to encourage parents and guardians to take measures to prevent sunburns in minors they care for; H.R. 1966 & S 946, the Henrietta Lacks Enhancing Cancer Research Act of 2019, regarding decreasing disparities in access to cancer clinical trials; Additional issues related to reducing health disparities in cancer clinical trials; Issues related to capturing racial and ethnic data demographic data for communities disproportionately affected by coronavirus; H.R. 2222 and S. 1107, the Women and Lung Cancer Research and Preventative Services Act; H.Res. 14 & S.Res. 223, Expressing support for the designation of DIPG Awareness Day H.R. 1730 and S. 741, the Cancer Drug Parity Act; Cannabis research issues, including S. 2032 Cannabidiol and Marihuana Research Expansion Act and S. 2400Expanding Cannabis Research and Information Act ; H.R. 2689 & S. 1438 the Breast Cancer Research Stamp Reauthorization Act H.R. 4078 & S. 2424 EARLY Act Reauthorization of 2019 S. 2497, the Dependent Income Exclusion Act; Issues related to HHS regulation of prescription drug prices; H.R. 4439, Creating Hope Reauthorization Act; H.R. 1730 and S. 741, the Cancer Drug Parity Act; H.R. 6556, the Gabriella Miller Kids First Research Act 2.0; H.R. 4439 & S. 4010, the Creating Hope Reauthorization Act; Issues related to cancer survivorship and transitions of care from oncology treatment back to primary care.

Client expense: $710,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Energy, Dept of, Environmental Protection Agency (EPA), Federal Reserve System, Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), Veterans Affairs, Dept of (VA), White House Office

Food and Drug Administration (FDA) draft "Guidance for Industry: New Dietary Ingredient Notifications and Related Issues." Supports efforts to encourage FDA to develop a legal path for CBD as a new dietary ingredient. (no bill number) H.R.3055 - Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020 S.1215 - National Defense Authorization Act for Fiscal Year 2020 S.2032 - A bill to expand research on the cannabidiol and marihuana. S.1717/H.R. 3142 - SNAP Vitamin and Mineral Improvement Act of 2019 H.R.1887 - National Institute of Nutrition Act H.R.1595 - Secure And Fair Enforcement Banking Act of 2019 S.2895 - SARMs Control Act of 2019 S.1790 - National Defense Authorization Act for Fiscal Year 2020 H.R.1865 - Further Consolidated Appropriations Act, 2020 H.R.5587 - To amend the Federal Food, Drug, and Cosmetic Act with respect to the regulation of hemp-derived cannabidiol and hemp-derived cannabidiol containing substances.

Client expense: $128,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, Treasury, Dept of, Vice President of the U.S.

H.R. 3797, Medical Marijuana Research Act, S. 2032, Cannabidiol and Marihuana Research Expansion Act, to lower the barriers of researching marijuana

Client expense: $40,000 · Firm income: Not reported

Government targets: Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Small Business Administration (SBA), White House Office

HR 171; HR 601; HR 3797; HR2843; HR 3884, S2032 - Marijuana Research Bills

Client expense: $240,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Food and Drug Administration (FDA) draft "Guidance for Industry: New Dietary Ingredient Notifications and Related Issues." Supports efforts to encourage FDA to develop a legal path for CBD as a new dietary ingredient. (no bill number) H.R.3055 - Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020 S.1215 - National Defense Authorization Act for Fiscal Year 2020 S.2032 - A bill to expand research on the cannabidiol and marihuana. S.1717/H.R. 3142 - SNAP Vitamin and Mineral Improvement Act of 2019 H.R.1887 - National Institute of Nutrition Act H.R.1595 - Secure And Fair Enforcement Banking Act of 2019 S.2895 - SARMs Control Act of 2019 S.1790 - National Defense Authorization Act for Fiscal Year 2020 H.R.1865 - Further Consolidated Appropriations Act, 2020 H.R.5587 - To amend the Federal Food, Drug, and Cosmetic Act with respect to the regulation of hemp-derived cannabidiol and hemp-derived cannabidiol containing substances.

Client expense: $165,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, Treasury, Dept of

H.R. 3502, Protecting People From Surprise Medical Bills Act, all provisions H.R. 3630, No Surprises Act, all provisions H.R. 2328, Community Health Investment, Modernization, and Excellence Act of 2019, all provisions S. 1895, Lower Health Care Costs Act, all provisions H.R. 5826, Consumer Protections Against Surprise Medical Bills Act of 2020, provisions relating to unanticipated billing for physician services, private contracting, rate setting S. 1531, Stopping The Outrageous Practice of (STOP) Surprise Medical Bills Act of 2019, all provisions H.R. 2279, Safe Step Act, all provisions S. 2032, Cannabidiol and Marihuana Research Expansion Act, all provisions H.R. 4004, Social Determinants Accelerator Act of 2019, all provisions H.R. 6102, Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2020, provisions relating to FDA oversight of laboratory developed tests H.R. 2339, Protecting American Lungs and Reversing the Youth Tobacco Epidemic Act of 2020, all provisions H.R. 4742, Protecting American Lungs Act of 2019, all provisions H.R. 5482, Providing Resources to End the Vaping Epidemic Now for Teenagers (PREVENT) Act of 2020, all provisions H.R. 6139, COVID-19 Health Care Worker Protection Act of 2020, all provisions S. 3559, A bill to provide emergency financial assistance to rural health care facilities and providers impacted by the COVID-19 emergency, all provisions H.R. 4100, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2019, all provisions S. 2892, Opioid Workforce Act of 2019, all provisions H.R. 2482, Mainstreaming Addiction Treatment Act of 2019, all provisions H.R. 1503, Orange Book Transparency Act of 2019, all provisions H.R. 1520, Purple Book Continuity Act of 2019, all provisions H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act, all provisions H.R. 4995, Maternal Health Quality Improvement Act of 2019, all provisions COVID-19 Pandemic Affordable Care Act (ACA) stabilization Immediate Relief for Rural Facilities and Providers Act of 2020, all provisions Prescription drug pricing/transparency/importation/value/prior authorizations Health reform/Universal coverage Retired physicians Public Health Emergency Fund financial assistance Protecting physician speech Opioids Surprise billing Health Disparities Physician Suicide/Burnout Telehealth AMA Privacy Framework Privacy legislation/administrative simplification 42 CFR Part 2, HIPAA Augmented Intelligence (AI)/federal health IT strategy Maternal mortality and morbidity COVID-19 emergency declaration/Section 1135 authority SARS-CoV-2 Testing COVID-19/ personal protective equipment (PPE) COVID-19/Controlled substances Diabetes prevention 21st Century Cures Act Pharmacy Benefits Manager (PBM)

Client expense: $6,630,000 · Firm income: Not reported

Government targets: Bureau of Citizenship & Immigration Services (BCIS), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP), SENATE, State, Dept of (DOS), U.S. Immigration & Customs Enforcement (ICE), Veterans Affairs, Dept of (VA), Vice President of the U.S., White House Office

Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, cancer survivorship, federal health care programs, genetic information, cancer, nutrition, tanning beds, clinical trials, skin cancer, cannabis research, and wellness, including: HR 6201, Families First Coronavirus Response Act HR 6704, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 HR 748, Coronavirus Aid, Relief, and Economic Security Act Issues related to surprise medical billing, including HR 3630, the No Surprises Act; S 1895, the Lower Health Care Costs Act; S 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019; Issues relating to curbing health care costs; H.R.647 & S. 2080, the Palliative Care and Hospice Education and Training Act; Anti-cancer medication cost-sharing parity respecting H.R. 1409; A national family caregiving strategy respecting S. 1719 and H.R. 1028; Access to medicines respecting FDA implementation of right to try law; Introduction of the S. 3404 & H.R. 6102, Verifying Accurate Leading-edge IVCT Development Act of 2020 or the VALID Act of 2020; H.R. 4897 & S. 2358 Women and Lung Cancer Research and Preventive Services Act of 2018; H. Res. 282, supporting initiatives to encourage parents and guardians to take measures to prevent sunburns in minors they care for; H.R. 1966 & S 946, the Henrietta Lacks Enhancing Cancer Research Act of 2019, regarding decreasing disparities in access to cancer clinical trials; Additional issues related to reducing disparities in cancer clinical trials; Issues related to improving quality of life for cancer survivorship; H.R. 2222 and S. 1107, the Women and Lung Cancer Research and Preventative Services Act; H.Res. 14 & S.Res. 223, Expressing support for the designation of DIPG Awareness Day H.R. 1730 and S. 741, the Cancer Drug Parity Act; Cannabis research issues, including S. 2032 Cannabidiol and Marihuana Research Expansion Act and S. 2400Expanding Cannabis Research and Information Act ; H.R. 2689 & S. 1438 the Breast Cancer Research Stamp Reauthorization Act H.R. 4078 & S. 2424 EARLY Act Reauthorization of 2019 S. 2497, the Dependent Income Exclusion Act; Issues related to HHS regulation of prescription drug prices; H.R. 4439, Creating Hope Reauthorization Act; H.R. 1730 and S. 741, the Cancer Drug Parity Act; S. 2911 - Seniors Prescription Drug Relief Act of 2019, would allow Medicare beneficiaries who reach an out of pocket cap to spread their payments over the course of the entire year; Issues related to cancer survivorship and transitions of care from oncology treatment back to primary care; and S. 1608, the Promoting Physical Activity for Americans Act.

Client expense: $730,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Energy, Dept of, Environmental Protection Agency (EPA), Federal Reserve System, Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), Veterans Affairs, Dept of (VA), White House Office

Issues related to controlled substances legislation and policy, including DOJ appropriations, IRS regulations, and taxation, and banking policies S.1028 - STATES Act H.R. 2093 - STATES Act H.R.5952 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2019 (section 542) H.R. 3884 - MORE Act of 2019 S.2032 - Cannabidiol and Marijuana Research Act FDA regulatory agenda

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2021, Provisions relating to NIH, substance use research Drug abuse research related issues, as follows: S. 2032, Cannabidiol & Marijuana Research Expansion Act Stop the Importation and Trafficking of Synthetic Analogues (SITSA) H.R.3797, Medical Marijuana Research Act of 2019 Public Law 115-334, Agriculture Improvement Act of 2018, Hemp related provision Barriers to research resulting from DEA scheduling Non Human Primates and Biomedical research H.R.601, Medical Cannabis Research Act H.R.2935/S.1622, Stopping Overdoses of Fentanyl Analogues Act S.2701, Federal Initiative to Guarantee Health by Targeting Fentanyl Act S.3148, Stopping Overdoses of Fentanyl Analogues Act Public Law 116-114, Temporary Reauthorization and Study of the Emergency Scheduling of Fentanyl Analogues Act H.R.5421, Stopping Illicit Trafficking Act of 2019 Monitor Coronavirus, Healthcare related issues

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

H.R. 3502, Protecting People From Surprise Medical Bills Act, all provisions H.R. 3630, No Surprises Act, all provisions S. 1531, Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, all provisions H.R. 2328, Community Health Investment, Modernization, and Excellence Act of 2019, all provisions S. 1895, Lower Health Care Costs Act, all provisions H.R. 2279, Safe Step Act, all provisions H.R. 2339, Reversing the Youth Tobacco Epidemic Act of 2019, all provisions H.R. 1503, Orange Book Transparency Act of 2019, all provisions H.R. 1520, Purple Book Continuity Act of 2019, all provisions H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act, all provisions S. 2032, Cannabidiol and Marihuana Research Expansion Act, all provisions 21st Century Cures Act 21st Century Cures 2.0 Affordable Care Act/stabilization Surprise Billing Nomination of Stephen Hahn, MD, as FDA Commissioner AMA Privacy Framework Augmented Intelligence (AI)/Information Blocking and Interoperability Opioids EHR Certification Quality Payment Program burdens Data Privacy 42 CFR Part 2 Nondiscrimination Anti-transgender violence Disaggregation of health outcomes related to Asian American and Pacific Islander (AAPI) Data Flavored e-cigarettes/Vaping Schedule II drugs/Annual production quota reduction Telehealth Drug Pricing/Transparency Drug Compounding Software as a Medical Device (SaMD) Health Disparities Physician economic impact

Client expense: $3,950,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Drug Enforcement Administration (DEA), Federal Bureau of Investigation (FBI), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Natl Drug Control Policy (NDCP), President of the U.S., SENATE, State, Dept of (DOS), Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA), White House Office

H.R. 3797, Medical Marijuana Research Act, S. 2032, Cannabidiol and Marihuana Research Expansion Act, to lower the barriers of researching marijuana

Client expense: $50,000 · Firm income: Not reported

Government targets: Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, White House Office

Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, cancer survivorship, federal health care programs, genetic information, cancer, nutrition, tanning beds, clinical trials, skin cancer, cannabis research, and wellness, including: Issues related to surprise medical billing, including HR 3630, the No Surprises Act; S 1895, the Lower Health Care Costs Act; S 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019; Issues relating to curbing health care costs; H.R.647 & S. 2080, the Palliative Care and Hospice Education and Training Act; Anti-cancer medication cost-sharing parity respecting H.R. 1409; A national family caregiving strategy respecting S. 1719 and H.R. 1028; Access to medicines respecting FDA implementation of right to try law; Issues relating to FDA regulation of laboratory tests, Verifying Accurate Leading-edge IVCT Development Act of 2018 or the VALID Act of 2018; H.R. 4897 & S. 2358 Women and Lung Cancer Research and Preventive Services Act of 2018; H. Res. 282, supporting initiatives to encourage parents and guardians to take measures to prevent sunburns in minors they care for; H.R. 1966 & S 946, the Henrietta Lacks Enhancing Cancer Research Act of 2019, regarding decreasing disparities in access to cancer clinical trials; Additional issues related to reducing disparities in cancer clinical trials; Issues related to improving quality of life for cancer survivorship; H.R. 2222 and S. 1107, the Women and Lung Cancer Research and Preventative Services Act; H.Res. 14 & S.Res. 223, Expressing support for the designation of DIPG Awareness Day H.R. 1730 and S. 741, the Cancer Drug Parity Act; Cannabis research issues, including S. 2032 Cannabidiol and Marihuana Research Expansion Act and S. 2400Expanding Cannabis Research and Information Act ; H.R. 2689 & S. 1438 the Breast Cancer Research Stamp Reauthorization Act H.R. 4078 & S. 2424 EARLY Act Reauthorization of 2019 HR___, Medical Records Fairness Act (Rep. Bill Foster, D-IL); S. 2497, the Dependent Income Exclusion Act; SJ Res 52, A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Secretary of the Treasury and the Secretary of Health and Human Services relating to "State Relief and Empowerment Waivers"; Issues related to prescription drug costs - H.R. 3, the Lower Prescription Drug Costs Now Act and S. 2543, the Prescription Drug Pricing Reduction Act of 2019; Issues related to HHS regulation of prescription drug prices; H.R. 4439, Creating Hope Reauthorization Act; H.R. 1730 and S. 741, the Cancer Drug Parity Act; S. 2546 & H.R. 2279, the Safe Step Act of 2019 - amends the Employee Retirement Income Security Act (ERISA) to require group health plans to provide an exception process for any medication step therapy protocol, tools used by health plans to control spending on patients medications, to help ensure patients are able to safely and efficiently access treatment; S. 2911 - Seniors Prescription Drug Relief Act of 2019, would allow Medicare beneficiaries who reach an out of pocket cap to spread their payments over the course of the entire year; Issues related to cancer survivorship and transitions of care from oncology treatment back to primary care; S. 1608, the Promoting Physical Activity for Americans Act; and Issues related to the nomination of Dr. Stephen Hahn to be Commissioner of the Food and Drug Administration.

Client expense: $1,650,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Energy, Dept of, Environmental Protection Agency (EPA), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), U.S. Agency for International Development (USAID), Veterans Affairs, Dept of (VA), White House Office

Food and Drug Administration (FDA) draft "Guidance for Industry: New Dietary Ingredient Notifications and Related Issues." Supports efforts to encourage FDA to develop a legal path for CBD as a new dietary ingredient. (no bill number) H.R.3055 - Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020 S.1215 - National Defense Authorization Act for Fiscal Year 2020 S.2032 - A bill to expand research on the cannabidiol and marihuana. S.1717/H.R. 3142 - SNAP Vitamin and Mineral Improvement Act of 2019 H.R.1887 - National Institute of Nutrition Act H.R.1595 - Secure And Fair Enforcement Banking Act of 2019 S.2895 - SARMs Control Act of 2019 S.1790 - National Defense Authorization Act for Fiscal Year 2020 H.R.1865 - Further Consolidated Appropriations Act, 2020

Client expense: $177,500 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of

Public Law 116-94, Further Consolidated Appropriations Act, 2020, Division A -- Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020, Provisions relating to NIH, substance use research, as follows: Drug abuse research related issues, as follows: S. 2032, Cannabidiol & Marijuana Research Expansion Act Stop the Importation and Trafficking of Synthetic Analogues (SITSA) H.R.3797, Medical Marijuana Research Act of 2019 Public Law 115-334, Agriculture Improvement Act of 2018, Hemp related provision Barriers to research resulting from DEA scheduling Non Human Primates and Biomedical research H.R.601, Medical Cannabis Research Act H.R.2935/S.1622, Stopping Overdoses of Fentanyl Analogues Act S.2701, Federal Initiative to Guarantee Health by Targeting Fentanyl Act

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

H.R. 3797, Medical Marijuana Research Act, S. 2032, Cannabidiol and Marihuana Research Expansion Act, to lower the barriers of researching marijuana

Client expense: $60,000 · Firm income: Not reported

Government targets: Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, White House Office

H.R. 3502, Protecting People From Surprise Medical Bills Act, all provisions H.R. 3630, No Surprises Act, all provisions H.R. 2328, Community Health Investment, Modernization, and Excellence Act of 2019, all provisions S.1531 - Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, all provisions S. 1895, Lower Health Care Costs Act, provisions relating to unanticipated billing for physician services, private contracting, rate setting H.R. 2279, Safe Step Act, all provisions H.R.1503, Orange Book Transparency Act of 2019, all provisions H.R.1520, Purple Book Continuity Act of 2019, all provisions H.R.987, Strengthening Health Care and Lowering Prescription Drug Costs Act, all provisions H.R.2482, Mainstreaming Addiction Treatment (MAT) Act of 2019, all provisions S.2032, Cannabidiol and Marihuana Research Expansion Act all provisions H.R. 8, Bipartisan Background Checks Act of 2019, all provisions Affordable Care Act (ACA) stabilization 21st Century Cures Act Surprise Billing/Independent dispute resolution (IDR) Health Data Privacy regulation Drug Prices Maternal Mortality and Healthcare Disparity Information blocking and interoperability Health reform/universal coverage Opioids/Substance use disorder Universal background checks for commercial gun purchases Health IT - Patient privacy, 42 CFR Part 2, HIPAA Telehealth Data privacy Supplemental Nutrition Assistance Program (SNAP) and the National School Lunch Program Section 1557 non-discrimination Misvalued codes Drug Compounding Clinical Laboratory/Laboratory developed tests (LDTs) Healthcare artificial/augmented intelligence (AI) Radiopharmaceuticals/training and experience requirements Gun violence Confidentiality of Substance Use Disorder Patient Records/comment period extension

Client expense: $4,570,000 · Firm income: Not reported

Government targets: Bureau of Citizenship & Immigration Services (BCIS), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Nuclear Regulatory Commission (NRC), President of the U.S., SENATE, State, Dept of (DOS), U.S. Commission on Civil Rights, U.S. Customs & Border Protection, Veterans Affairs, Dept of (VA), White House Office